Table 3.
Correlation of plasma AR copy number and PSA kinetics.
| AR Normal | AR Gain | p | |
|---|---|---|---|
| Baseline PSA (ng/mL) (IQR) | 20.64 (7.16 to 77.00) | 123.40 (34.69 to 291.0) | <0.0001 |
| PSA response rate (yes vs. no), n (%) | 79 (54.5) vs. 66 (45.5) | 21 (28.8) vs. 52 (71.2) | 0.0003 |
| Maximum % PSA decline (IQR) | −78.93 (−91.26 to −45.16) | −52.36 (−74.58 to −22.99) | 0.003 |
| PSA response rate at week 12 (>30%), n (%) | 91 (81.2) vs. 21 (18.8) | 26 (65.0) vs. 14 (35.0) | 0.037 |
| PSA response rate at week 12 (>50%), n (%) | 77 (68.7) vs. 35 (31.3) | 20 (50.0 vs. 20 (50.0) | 0.035 |
| PSA response rate at week 12 (>90%), n (%) | 35 (31.2) vs. 77 (68.8) | 4 (10.0) vs. 36 (90.0) | 0.008 |
| Nadir PSA value (ng/mL) (IQR) | 3.04 (0.95 to 19.53) | 47.09 (14.85 to 149.30) | <0.0001 |
| Time to PSA nadir (months) (IQR) | 2.96 (1.76 to 6.61) | 1.81 (0.92 to 2.55) | 0.0002 |
| PSA nadir DT (months) (IQR) | −2.19 (−3.91 to −1.00) | −1.44 (−3.44 to −0.77) | 0.463 |
| PSA DT velocity from baseline to nadir (ng/mL/month) (IQR) | −3.02 (−1.43 to −1.26) | −16.68 (−6.47 to −4.06) | 0.001 |
| PSA DT from nadir (months) (IQR) | 3.60 (2.10–7.71) | 2.40 (1.40–3.40) | 0.001 |
| PSA DT velocity from nadir (ng/mL/month) (IQR) | 2.8 (0.7–14.3) | 27.8 (9.6–116.1) | <0.0001 |
| Time to PSA PD (months) (IQR) | 7.07 (3.78 to 13.09) | 3.55 (1.91 to 6.22) | <0.0001 |
Abbreviations. AR, androgen receptor; DT, double timing; IQR, interquartile range; PD, progression disease; PSA, prostate specific antigen.